Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2026927
Abstract: ABSTRACT Introduction Tyrosine kinase 2 (TYK2) is a member of the JAK family class of kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The therapeutic value of targeting this… read more here.
Keywords: review; inhibitors potential; selective tyk2; tyk2 ... See more keywords